Further studies with propranolol in psychotic patients
PsychopharmacologyPublished 1 January 1972
A Atsmon, I Blum, Meir Steiner, Arje Latz, H Wijsenbeek
Citations107
SJR quartileQ1
SJR score1.16
SNIP0.97
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A striking correlation was noted between the effect of propranolol and of pre-treatment urinary excretion of total cateoholamines and 3-methoxy-4-hydroxyphenylglycol (MHPG).
Abstract
12 schizophrenic patients were treated with large doses of propranolol, a beta-adrenergic blocking agent. 5 patients were much improved and 3 patients showed some improvements. A striking correlation was noted between the effect of propranolol and of pre-treatment urinary excretion of total cateoholamines and 3-methoxy-4-hydroxyphenylglycol (MHPG).
Keywords
PsychologyMedicine
SciencePossible Etiology of Schizophrenia: Progressive Damage to the Noradrenergic Reward System by 6-Hydroxydopamine
481 Citations1971Larry Stein, C. David Wise
Episodic or continuous formation of endogenous 6-hydroxydopamine in man as a result of a genetically determined enzymatic error could selectively damage the binding capacity and, eventually, the structural integrity of the noradrenergic reward mechanism.
HeartCardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39,089-Ba.
44 Citations1968Thierry Grandjean, J.-L. Rivier
Patients with organic disease of the left heart were given intravenously of propranolol, and its circulatory effects were assessed during the course of standard pre-operative catheterization of the heart, and these effects were compared with those of CIBA 39,089-Ba, a new specific beta-adrenergic blocking agent.
New England Journal of MedicineSimultaneous Urinary Assays for the Combined Metanephrines and 3-Methoxy-4-Hydroxyphenylglycol in Patients with Pheochromocytoma and Primary Hypertension
33 Citations1965Robert L. Wolf, Milton Mendlowitz +2 more
The discovery, by Armstrong and McMillan,1 in 1957, of the presence of the catecholamine metabolite, 3-methoxy-4-hydroxymandelic acid (VMA), in human urine stimulated investigations that resulted in the development of VMA antagonists.